Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas research hub

An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

This study looks at a new drug, nanatinostat, combined with an anti-virus medicine, valganciclovir, for people with specific types of lymphoma that have returned or not responded to previous treatments. It aims to see how well this combination shrinks the cancer.